Linked Life Data

16146883

Source:http://linkedlifedata.com/resource/pubmed/id/16146883

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2005-9-8
pubmed:abstractText
Cord blood (CB) cells are being used increasingly as a source of hematopoietic cells to support high dose chemotherapy. However, CB units contain low numbers of cells, including CD34+ cells, and thus their use is associated with significant delays in engraftment of neutrophils and platelets. Exvivo expansion of CB has been proposed to increase the numbers of cells available. We and others have reported the requirement of CD34 selection for optimal expansion of CB products'; however, the selection of frozen CB products in clinical trials results in significant loss of CD34+ cells, with a median recovery of 50, but less than 40% recovery in more than one-third of products. In the present studies we evaluated the potential of mesenchymal stem cells (MSC) to support ex vivo expansion of unselected CB products.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1465-3249
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
311-7
pubmed:dateRevised
2008-4-24
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells.
pubmed:affiliation
Johns Hopkins University School of Medicine Sidney Kimmel Comprehensive Cancer Center Baltimore, MD 21231, USA.
pubmed:publicationType
Journal Article